GH001 Aerosol Phase 1 Trial - Pharmacokinetics and Safety in Healthy Subjects

A new Phase 1 clinical trial registration appears on ClinicalTrials.gov for GH001, a 5-methoxy N,N-dimethyltryptamine compound delivered via a proprietary aerosol device. The trial's primary endpoints are single-dose pharmacokinetics and safety/tolerability in healthy adult subjects.

Affected parties include clinical research organizations conducting early-phase studies, sponsors of psychedelic or psychoactive compound programs, and institutional review boards reviewing similar protocols. Trial registration on ClinicalTrials.gov is a standard procedural requirement for federally-funded clinical research and does not itself create compliance obligations.